| 货号 | BAF1433 |
| 描述 | For ELISA the Antibody Pairs information：Capture antibody：MAB14332；Detection antibody：BAF1433; and protein: 1433-OP-050 |
| 别名 | BNSP; Bone sialoprotein 1; Eta-1; MGC110940; Nephropontin; OPN; osteopontin; secreted phosphoprotein 1bone sialoprotein I, early T-lymphocyteactivation 1); secreted phosphoprotein-1 (osteopontin, bone sialoprotein); Spp1; SPP-1; SPP1/CALPHA1 fusion; Urinary stone protein; uropontin | 全称 | Secreted Phosphoprotein 1 [BNSP] |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) Immunocytochemistry(5-15 µg/mL) ELISA Capture (Matched Antibody Pair)(2-8 µg/mL ) ELISA Detection (Matched Antibody Pair)(0.1-0.4 µg/mL ) ELISA Standard ( ) |
| 目标/特异性 | Detects human Osteopontin/OPN in ELISAs and Western blots. In sandwich ELISAs, less than 0.2% cross-reactivity with recombinant mouse (rm) Osteopontin and bovine Osteopontin is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunocytochemistry: 5-15 µg/mL ELISA Capture (Matched Antibody Pair): 2-8 µg/mL ELISA Detection (Matched Antibody Pair): 0.1-0.4 µg/mL ELISA Standard : |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 6696 (Human); 20750 (Mouse); 25353 (Rat); 281499 (Bovine) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Human milk-derived Osteopontin/OPN |
| 生物活性 | Human |
| 标记 | Biotin |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Osteopontin (OPN, previously also referred to as transformation-associated secreted phosphoprotein, bone sialoprotein I, 2ar, 2B7, early T lymphocyte activation 1 protein, minopotin, calcium oxalate crystal growth inhibitor protein), is a secreted, highly acidic, calcium-binding, RGD-containing, phosphorylated glycoprotein originally isolated from bone matrix (1). Subsequently, OPN has been found in kidney, placenta, blood vessels and various tumor tissues. Many cell types (including macrophages, osteoclasts, activated T-cells, fibroblasts, epithelial cells, vascular smooth muscle cells, and natural killer cells) can express OPN in response to activation by cytokines, growth factors or inflammatory mediators. Elevated expression of OPN has also been associated with numerous pathobiological conditions such as atherosclerotic plaques, renal tubulointerstitial fibrosis, granuloma formations in tuberculosis and silicosis, neointimal formation associated with balloon catheterization, metastasizing tumors, and cerebral ischemia. Human OPN cDNA encodes a 314 amino acid (aa) residue precursor protein with a 16 aa residue predicted signal peptide that is cleaved to yield a 298 aa residue mature protein with an integrin binding sequence (RGD), and N- and O-glycosylation sites. By alternative splicing, at least three human OPN isoforms exist. OPN has been shown to bind to different cell types through RGD-mediated interaction with the integrins alpha vbeta1, alpha vbeta3, alpha vbeta5, and non-RGD-mediated interaction with CD44 and the integrins alpha 8beta1 or alpha 9beta1. OPN exists both as a component of extracellular matrix and as a soluble molecule. Functionally, OPN is chemotactic for macrophages, smooth muscle cells, endothelial cells and glial cells. OPN has also been shown to inhibit nitric oxide production and cytotoxicity by activated macrophages. Human, mouse, rat, pig and bovine OPN share from approximately 40% - 80% amino acid sequence identity. Osteopontin is a substrate for proteolytic cleavage by thrombin, enterokinase, MMP-3 and MMP-7. The functions of OPN in a variety of cell types were shown to be modified as a result of proteolytic cleavage (2, 3). |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|